# Exploring the Role of MOTS-c in Alzheimer's Disease Biomarkers

Canonical source: https://retacompare.com/research/exploring-the-role-of-mots-c-in-alzheimer-s-disease-biomarkers

Mitochondrial & Longevity · 2025-11-09


    MOTS-c may serve as an early biomarker for Alzheimer's disease, reflecting its potential in neuroprotection. This mitochondrial-derived peptide, alongside Humanin, exhibits a decline in expression with aging and neurodegenerative conditions. Understanding the implications of MOTS-c in Alzheimer's disease could enhance early detection and therapeutic strategies.

 What this study examined

This study investigated the expression levels of Humanin (HN) and MOTS-c in relation to Alzheimer's disease (AD) and mild cognitive impairment (MCI). A case-control design was employed, involving patients diagnosed with AD and MCI, as well as individuals experiencing subjective cognitive decline (SCD) serving as controls. Researchers quantified gene expression from blood and plasma samples, normalizing the data to mitochondrial DNA copy number (mtDNA-CN), and utilized ELISA to measure plasma protein concentrations of HN and MOTS-c.

 Why it matters for MOTS-c research

The findings of this study are significant for the ongoing research into MOTS-c, particularly its potential as a biomarker for Alzheimer's disease. The differential expression of MOTS-c and HN transcripts among the study groups suggests that these peptides could play a role in the neurodegenerative process. Additionally, the study highlights the importance of examining mRNA levels rather than protein concentrations, as the latter did not effectively distinguish between AD and MCI, emphasizing the need for further exploration of the underlying mechanisms.

 Key findings

Blood and plasma transcript levels of MOTS-c were significantly reduced in Alzheimer's patients compared to those with subjective cognitive decline.

Plasma protein levels of HN and MOTS-c did not show significant differences between Alzheimer's and MCI groups.

HN mRNA exhibited faster degradation rates, while MOTS-c mRNA showed delayed but stable recovery.

The study suggests that transcript levels of these mitochondrial-derived peptides could serve as early biomarkers for Alzheimer's disease.

Research indicates a potential relationship between MOTS-c expression and the conversion from MCI to AD.

 How MOTS-c works (background)

MOTS-c is a 16-amino acid peptide encoded by mitochondrial DNA, playing a crucial role in cellular metabolism and stress response. It is known to exert neuroprotective effects, particularly in the context of neurodegenerative diseases. The peptide is involved in regulating mitochondrial function, promoting cellular resilience against oxidative stress, and influencing metabolic pathways. By enhancing mitochondrial biogenesis and function, MOTS-c may help mitigate the neuronal damage associated with Alzheimer's disease. Understanding its mechanisms can aid in developing targeted therapies that leverage its protective properties.

 Practical takeaways for researchers

Researchers focusing on Alzheimer's disease should consider the implications of MOTS-c and HN as potential biomarkers for early detection and monitoring of disease progression. The study emphasizes the importance of measuring transcript levels, which may provide more reliable insights than protein concentrations. Future research could explore the therapeutic applications of MOTS-c, particularly in enhancing mitochondrial function and neuroprotection in neurodegenerative contexts. Investigating the relationship between MOTS-c expression and cognitive decline could further elucidate its role in Alzheimer's pathology.

 FAQ

 What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide that has been implicated in neuroprotection and metabolic regulation.

 How does MOTS-c relate to Alzheimer's disease?

Research indicates that lower levels of MOTS-c may be associated with Alzheimer's disease, suggesting its potential as a biomarker for early detection.

 Can MOTS-c be used therapeutically?

While research is ongoing, MOTS-c's role in enhancing mitochondrial function suggests it may have therapeutic potential in neurodegenerative diseases.

 Source: PubMed · Int J Mol Sci · published 2025-11-09.

## Sources

- PubMed · Int J Mol Sci: https://pubmed.ncbi.nlm.nih.gov/41303353/